PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Kemin Industries, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

European Commission Authorizes CLOSTAT™ for its’ Use in Laying Hens and Breeders - Natural patented solution supports intestinal health and improves profitability - Kemin.com
European Commission Authorizes CLOSTAT™ for its’ Use in Laying Hens and Breeders

 

NewswireToday - /newswire/ - Herentals, Belgium, 2015/06/09 - Natural patented solution supports intestinal health and improves profitability - Kemin.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

In the latest meeting of the Standing Committee Animal Nutrition, the European Commission has voted positive on the authorization of the use of Bacillus subtilis ATCCPTA-6737 PB6, known as CLOSTAT, in laying hens and breeders. The commission’s ruling completes the approval process for usage in all poultry species (layers, breeders, broilers, turkeys, and minor species) and in piglets. The European Commission recognizes that CLOSTAT accentuates growth and is safe for the birds, human health and the environment.

“We are pleased by the European Commission’s positive decision,” said John Springate, president of the animal nutrition and health division of Kemin in Europe. This vote supports multiple field trials on millions of birds. The decision will make it possible for CLOSTAT to help more veterinarians, farmers and nutritionists with an effective and cost-effective way to maintain gut health, improve outcomes and profitability.

It is well known that intestinal integrity and microbial balance in commercial poultry and livestock are important factors that can determine the capacity of the animal to reach its full genetic potential for growth and yield due to the full utilization of the nutrients in their diets. In laying hens and breeders, just as in broilers, turkeys and piglets, pathogenic Clostridium spp. can cause diarrhea, poor nutrient assimilation, wet litter, dirty eggs and in leg problems resulting in flock impairment with low zootechnical parameters.

Over the years, several field trials involving millions of birds have proven CLOSTAT is a natural solution to suppress C. perfringens and promotes beneficial bacteria such as Lactobacillus spp. and Bifidobacterium spp. The product contains a natural spore forming bacteria offering interesting advantages for long term storage without refrigeration or need for encapsulation; it is heat stable in the feed pelleting processes. CLOSTAT is compatible with most of the standard coccidiostats used in EU, as well as organic acids used in water application.

Testimonials from producers and veterinarians across the world indicate that CLOSTAT works effectively in the maintenance of a balanced gastro intestinal tract, reducing intestinal Clostridial disorders while supporting the responsible use of antibiotics minimizing resistance pressure in the environment.

In view of current animal production challenges, CLOSTAT supports intestinal health, improves welfare farm status as well as reducing mortality rates and medication costs through its continuous use. It is a true natural preventive solution to be considered by the egg and breeder industry.

Kemin Inspired Molecular Solutions™
Kemin (kemin.com) provides “inspired molecular solutions” specifically developed to provide nutrition and health benefits for humans and animals. Committed to feed and food safety, Kemin maintains top-of-the-line manufacturing facilities where approximately 500 specialty ingredients are made for the global feed and food industries as well as the health, nutrition and beauty markets. A privately held, family-owned and operated company, Kemin has nearly 2,000 employees and operates in 90 countries with manufacturing facilities in Belgium, Brazil, China, India, Italy, Portugal, Singapore, South Africa and the United States.

™® Trademarks of Kemin Industries, Inc.
Certain statements may not be applicable in all geographical regions. Product labeling and associated claims may differ based upon government requirements.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Kemin Industries, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


European Commission Authorizes CLOSTAT™ for its’ Use in Laying Hens and Breeders

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tin Mariën - Kemin.com 
+32 14 28 62 60 tin.marien[.]kemin.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Kemin Industries, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Kemin Industries, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)